AU2021442702A1 - Method for allowing immune cells infiltration in tumors - Google Patents

Method for allowing immune cells infiltration in tumors Download PDF

Info

Publication number
AU2021442702A1
AU2021442702A1 AU2021442702A AU2021442702A AU2021442702A1 AU 2021442702 A1 AU2021442702 A1 AU 2021442702A1 AU 2021442702 A AU2021442702 A AU 2021442702A AU 2021442702 A AU2021442702 A AU 2021442702A AU 2021442702 A1 AU2021442702 A1 AU 2021442702A1
Authority
AU
Australia
Prior art keywords
subject
cancer
metastatic
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021442702A
Other languages
English (en)
Inventor
Mario Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alethia Biotherapeutics ULC
Original Assignee
Alethia Biotherapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics ULC filed Critical Alethia Biotherapeutics ULC
Publication of AU2021442702A1 publication Critical patent/AU2021442702A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021442702A 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors Pending AU2021442702A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (1)

Publication Number Publication Date
AU2021442702A1 true AU2021442702A1 (en) 2023-11-30

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021442702A Pending AU2021442702A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors
AU2022266854A Pending AU2022266854A1 (en) 2021-04-27 2022-04-26 Method for allowing immune cells infiltration in tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022266854A Pending AU2022266854A1 (en) 2021-04-27 2022-04-26 Method for allowing immune cells infiltration in tumors

Country Status (10)

Country Link
US (2) US20240199758A1 (https=)
EP (2) EP4329801A4 (https=)
JP (2) JP2024516416A (https=)
KR (2) KR20240014052A (https=)
CN (2) CN117479955A (https=)
AU (2) AU2021442702A1 (https=)
CA (2) CA3173786A1 (https=)
IL (2) IL307954A (https=)
MX (2) MX2023012766A (https=)
WO (2) WO2022226623A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors
MX2024009671A (es) * 2022-02-07 2024-08-19 Alethia Biotherapeutics Inc Terapia de combinación para uso en el tratamiento del cáncer de pulmón de células no pequeñas.
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Also Published As

Publication number Publication date
KR20240013743A (ko) 2024-01-30
WO2022226637A1 (en) 2022-11-03
EP4329801A1 (en) 2024-03-06
IL307961A (en) 2023-12-01
CN117479955A (zh) 2024-01-30
CA3173786A1 (en) 2022-10-27
EP4329802A1 (en) 2024-03-06
IL307954A (en) 2023-12-01
CA3173797A1 (en) 2023-10-05
AU2022266854A9 (en) 2023-12-07
JP2024516416A (ja) 2024-04-15
AU2022266854A1 (en) 2023-11-30
KR20240014052A (ko) 2024-01-31
EP4329802A4 (en) 2025-09-03
EP4329801A4 (en) 2025-05-14
JP2024516818A (ja) 2024-04-17
MX2023012766A (es) 2024-02-23
US20240199758A1 (en) 2024-06-20
WO2022226623A1 (en) 2022-11-03
CN117479956A (zh) 2024-01-30
US20240317884A1 (en) 2024-09-26
MX2023012768A (es) 2023-11-13

Similar Documents

Publication Publication Date Title
KR102679155B1 (ko) Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
JP7471227B2 (ja) 抗組織因子抗体－薬物コンジュゲートおよびがんの治療におけるその使用
KR20140009275A (ko) 파클리탁셀 및 트라스투주맙-mcc-dm1에 의한 her2-양성 암의 치료
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
CN110036030A (zh) 癌症的组合疗法
CN113939309A (zh) 使用sEphB4-HSA融合蛋白治疗癌症
JP2021527083A (ja) ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2023011902A (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
JP2025542297A (ja) 肺癌の組み合わせ療法
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
WO2026039321A1 (en) Methods for treating prostate cancer
WO2023164662A1 (en) Treatment of squamous non small cell lung cancer
KR20250115399A (ko) 항-ddr1 항체를 사용한 암 치료 방법
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
KR20250112805A (ko) 항-ddr1 항체 및 면역관문 억제제를 사용한 암 치료 방법
HK40109234A (zh) 用於治疗癌症的方法和组合物
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака
HK40010257B (en) Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO ALETHIA BIOTHERAPEUTICS ULC